MedPal AI (LSE:MPAL) has completed a £3 million fundraising through the placement of 120 million new shares at 2.5 pence each, representing a 13% discount to the previous closing price. The raise attracted new institutional investors and includes the appointment of OAK Securities as joint broker, aimed at strengthening the company’s institutional reach. Following the transaction, MedPal’s total issued share capital will increase to 612,441,036 shares, with the new shares expected to begin trading on AIM on 22 April 2026.
The company plans to use the proceeds to expand marketing efforts for its MedPal.clinic weight-loss platform, support working capital amid rising NHS dispensing volumes and growth in its care home segment, and fund key senior hires. Investment will also go toward completing robotic capacity at its Runcorn facility. Management believes the funding will accelerate its path toward profitability by supporting the rollout of commercial partnerships and reinforcing its presence in the fast-growing UK markets for GLP-1 treatments and digital healthcare.
More about MedPal AI Plc
MedPal AI Plc is a UK-based digital health and artificial intelligence company focused on its MedPal Health OS platform, which integrates AI-driven wellness tools, clinical services, and automated pharmacy fulfilment. Through its subsidiary MedPal Limited, the group operates a круглосуточный AI-powered robotic pharmacy distribution centre handling NHS and private prescriptions across the UK, alongside a rapidly expanding GLP-1 weight-loss clinic and B2B supply services for care homes.
Leave a Reply